期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

基于数据库的全球胰岛素科技研发及行业市场分析

Analysis on Global Insulin Scientific Research and Development as Well as Industry Market Status Based on Database
下载PDF
导出
摘要 综合运用Web of Science、Innograph以及Thomsonreuters Cortellis数据库对胰岛素进行专题检索,通过文献、专利计量分析以及行业销售数据统计,找出全球在胰岛素基础研究、专利以及市场销售领域的重点机构以及重要产品,揭示该领域科技研发及市场状况。 The paper makes subject retrieval by Web of Science, Innograph and Thomsonreuters Cortellis database. Through litera- ture and patent bibliometric analysis as well as sales data statistics, main institutions and important products in the worldwide in insulin basic research, patent and marketing are found out, revealing the scientific research and development as well as market status in this field.
作者 孙晓北 王敏 杨渊 李扬 高东平
机构地区 中国医学科学院医学信息研究所
出处 《医学信息学杂志》 CAS 2014年第12期51-55,共5页 Journal of Medical Informatics
关键词 胰岛素 文献计量 专利 行业 Insulin Reference statistics Patent Industry
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献6

二级参考文献9

  • 1Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med, 2010, 362: :090-1101.
  • 2The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the develop- ment and progression of long-term complications in insulin-de- pendent diabetes mellitus. N Engl J Med, 1993,329 : 977-986.
  • 3Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 dia- betes. N Engl J Med, 2005,353:2643-2653.
  • 4UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in pa- tients with type 2 diabetes (UKPDS 33). Lancet 1998, 352 (9131) : 837-853.
  • 5Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008,359 : 1577-1589.
  • 6Jonassen IB, Havelund S, Ribel U, et al. Insulin Degludec ls a New Generation Ultra-Long Acting Basal Insulin with a Unique Mechanism of Protraction Based on Multi-Hexamer Formation. Diabetes, 2010,59 (Suppl. 1): A11 (39-OR).
  • 7Heise T, Hermanskl L, Nosek L, et al. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia 2010;53(Suppl. 1):S387 (Poster 971).
  • 8Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-gener- ation ultra-long-acting insulin compared with insulin glargine. Diabetes Care, 2011,34: 661-665.
  • 9Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ul- tra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabe- tes: a 16-week, randomised, open-label, phase 2 trial. Lancet, 2011,377:924-931.

共引文献13

医学信息学杂志
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部